Combining drug-disease and economic modelling to inform drug development decisions
Related Experiment Video
Updated: Oct 3, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs
Published on: June 21, 2018
1Pharsight Corporation, 800 W. El Camino Real, Suite 200, 94040, tel: +1 650 314 3800 fax: +1 650 314 3810, Mountain View, CA, USA
Abstract:
Drug-disease models and clinical trial simulations are increasingly being used to support trial design and treatment optimization decisions. Less widely recognized is their potential for guiding strategic development decisions. These decisions require economic valuation of the potential product profile of efficacy, safety, ease of use, and so on. This review presents a disguised case study that uses drug-disease modelling to generate a probabilistic forecast of a drug's profile. This allows a quantitative analysis of whether to pursue a once-a-day regimen for an antiretroviral being tested twice-a-day in Phase II trials, and if so, at what dose and for which market segments.
Related Concept Videos
Pharmacodynamic Models: Additive and Proportional Drug Effect Model
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Pharmacokinetic–Pharmacodynamic Relationship: Problems
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Pharmacodynamic Models: Overview
Pharmacokinetic–Pharmacodynamic Relationship: Model Components
